NCT05518409 is a NA clinical trial of Detection of cytof in peripheral PBMC in Alzheimer Disease, sponsored by First Affiliated Hospital of Zhejiang University.

Who is sponsoring NCT05518409?

NCT05518409 is sponsored by First Affiliated Hospital of Zhejiang University.

What drugs are being tested in NCT05518409?

Interventions in NCT05518409: Detection of cytof in peripheral PBMC, Donepezil for patients with AD and DLB.

What condition does NCT05518409 study?

NCT05518409 studies Alzheimer Disease, Lewy Body Disease, Neurodegenerative Diseases.

Is NCT05518409 still recruiting?

NCT05518409 is currently status unknown. Last updated 14 September 2023.

Last reviewed 2023-09-14 · How we verify

NCT05518409

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunohistochemical Study of Neurodegenerative Diseases

Status unknown NA Last updated 14 September 2023

What this trial tests

NA trial testing Detection of cytof in peripheral PBMC in Alzheimer Disease in 100 participants. Status unknown.

Timeline

1 April 2022

Primary endpoint
1 December 2023

30 December 2023

Quick facts

Lead sponsor	First Affiliated Hospital of Zhejiang University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	100
Start date	1 April 2022
Primary completion	1 December 2023
Estimated completion	30 December 2023
Sites	1 location across China

Drugs / interventions tested

Detection of cytof in peripheral PBMC — full drug profile →
Donepezil for patients with AD and DLB — full drug profile →

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →
Lewy Body Disease — all drugs for Lewy Body Disease →
Neurodegenerative Diseases — all drugs for Neurodegenerative Diseases →

Sponsor

First Affiliated Hospital of Zhejiang University

Who can join

Adults 55 to 100, any sex, with Alzheimer Disease or Lewy Body Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The subject uses cytof to analyze PBMC of sporadic AD and DLB, which is used to reveal the differences in immune characteristics of the two diseases at the single-cell level, build immune models for specific diseases, and define these two neurodegenerative diseases with high precision from the level of molecular immunity. To provide basis for further study of the immunohistochemical differences between the two diseases, and provide objective support for clinical diagnosis and differential diagnosis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Peripheral Single-Cell Immune Characteristics Contribute to the Diagnosis of Alzheimer's Disease and Dementia With Lewy Bodies.
Qiu C, Zhang D, Wang M, Mei X, et al · · 2025 · cited 5× · PMID 39754303 · DOI 10.1111/cns.70204

Verify or expand the search:

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other First Affiliated Hospital of Zhejiang University trials

Trials by the same sponsor.

NCT07537192 — Inulin-Spirulina Co-intervention for Insomnia Disorder · NA · not yet recruiting
NCT07510867 — 18F-FAPI PET/CT and MRI in Gastric Cancer · not yet recruiting
NCT07589647 — Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic D · NA · recruiting
NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07468162 — Characteristic Electroencephalogram of General Anesthesia · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05518409 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Zhejiang University
Last refreshed: 14 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05518409.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing